Abstract The 2001 World Health Organization (WHO) treatise on the classification of
hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of …

The discovery of an identical mutation (V617F) of the JAK2 gene in patients with
polycythemia vera, essential thrombocythemia, and myelofibrosis—the principal …

Abstract Disease overview Polycythemia Vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms respectively characterized by erythrocytosis and …

The Janus kinase 2 mutation, JAK2 617V> F, is myeloid neoplasm-specific; its presence
excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other …

Abstract Interferon-α (IFN-α) is a nonleukemogenic treatment of polycythemia vera (PV) able
to induce cytogenetic remissions. Its use is limited by toxicity, leading to treatment …

We studied the relationship between JAK2 (V617F) mutant allele burden and clinical
phenotype, disease progression and survival in patients with polycythemia vera (PV). The …

Disease overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms, respectively characterized by erythrocytosis and …

To update oncologists on pathogenesis, contemporary diagnosis, risk stratification, and
treatment strategies in BCR-ABL1–negative myeloproliferative neoplasms, including …

Myeloproliferative neoplasms (MPN) are clonal stem cell diseases, first conceptualized in
1951 by William Dameshek, and historically included chronic myeloid leukemia (CML) …

The aim of this study was to determine whether the burden of JAK2 V617F allele correlated
with major clinical outcomes in patients with polycythemia vera (PV). To this end, we …